Close Menu

NEW YORK – The US Food and Drug Administration has approved Foundation Medicine's FoundationOne Liquid CDx, a multi-cancer comprehensive liquid-biopsy test, for multiple companion diagnostic indications including one for prostate cancer and three for lung cancer.

The approval is the agency's second for a comprehensive liquid biopsy, following on the heels of a nod earlier this month for Guardant Health's Guardant360 CDx test.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.